This 3M Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Analysts upgraded First Financial, 3M, Synopsys, Humana and Stem, raising targets for four while maintaining Stem’s $7 target.
Stocks · News reference
Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M Estimate
Lakefront Biotherapeutics (NASDAQ:LKFT) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $(13.52) by 102.14 percent. This is a 120 percent increase over losses of $(1.45) per
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Crude Oil Gains 1%; Cintas Earnings Top Views
U.S. stocks fell Wednesday, led by a 1.1% Nasdaq drop. Cintas beat estimates and raised guidance; oil gained while gold, silver and copper declined.
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.